This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.

Inclusion Criteria:

• Males and females
• Intracerebral Hemorrhage as the cause of stroke symptoms
• Onset of symptoms within 6 hours
• Full functional independence prior to the present stroke

Exclusion Criteria:

• Unconsciousness
• Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition.
• Severe illness with life expectancy less than 6 months.
• Known severe kidney disorder.
• Current known alcohol or illicit drug abuse or dependence.
• Pregnant or breast-feeding.
• Treatment with acetazolamide and methotrexate is not permitted during the infusion
• Participation in a previous clinical study within 7 days.
• Meets all other exclusion criteria